significantnew treatment
Zanubrutinib FDA-approved for WM
Waldenström's Macroglobulinemia →Summary
In August 2021, zanubrutinib received FDA approval for WM based on the ASPEN trial, making it the second BTK inhibitor approved for the disease. Zanubrutinib's more selective BTK inhibition profile results in fewer off-target effects including significantly lower rates of atrial fibrillation compared to ibrutinib, establishing it as a better-tolerated alternative.
Related treatments
More from Waldenström's Macroglobulinemia
incrementalTreatment update
Emerging CAR-T and bispecific antibody approaches for WM
incrementalNew research
BTK degraders (PROTACs) enter clinical trials for B-cell malignancies
significantTreatment update
Pirtobrutinib shows activity in covalent BTK inhibitor-pretreated WM
incrementalNew research
Genomics-guided treatment selection advances in WM
ID: waldenstroms-macroglobulinemia-update-9Type: new_treatmentImpact: significant